anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: The Scandinavian Journal of Work, Environment & Health (SJWEH) was established half a century ago. This paper provides an overview of research on musculoskeletal disorders (MSD) published over these 50 years. Three themes are described: risk assessment, interventions to prevent work-related MSD, and interventions to support work participation. Finally, implications for future research are highlighted.
METHODS: A systematic literature search was performed for all papers on MSD published in SJWEH. Each paper was coded on several criteria including research topic, type of MSD, risk factor(s), and number of citations. Findings were tabulated, and discussions within the author team defined the main results and future research directions.
RESULTS: The search resulted in 1056 papers, of which 474 were included. The most reported-on MSD was low-back pain (LBP, 18%) and the most reported-on work-related risk factors were physically demanding work (14%) and psychosocial factors (12%). Research has contributed to improving case definitions, refining work-related exposure criteria, and recognizing the varying importance of physical and psychosocial factors across different MSD. Research on the association between work-related risk factors and LBP continues to emerge. Effective interventions for prevention of MSD are characterised by sufficient exposure reduction, while supporting work participation requires integrating health care, with multidisciplinary actions directed at factors involving the worker, employer, and workplace.
CONCLUSION: Research has provided valuable insights into risk assessment, interventions for preventing work-related MSD, and supporting work participation. Intervention studies remain warranted and new areas include adopting whole-system approaches to prevent work-related MSD and promoting the concept of musculoskeletal health.
The invention provides a micelle composition, a preparation method and application thereof, relating to the field of daily chemicals. The micelle composition comprises the following components in parts by weight: 20-60 parts of polyglycerol and/or polyethylene glycol surfactant, 20-60 parts of regulator and 0-60 parts of amphoteric surfactant, wherein the regulator comprises at least one of saccharide regulator, glucoside regulator and polyalcohol regulator. The micelle composition disclosed by the invention is mild in components, free of irritation to skin and good in moisture retention. The functions of all components are fully exerted by utilizing the mutual influence among all the components and through reasonable control and scientific collocation of the adding amount of all the components. The invention provides a preparation method of a micelle composition, which is simple and rapid. When the micelle composition provided by the invention is applied to a cleaning and skin-care product, the problems of poor decontamination capability, skin irritation and low cost performance of the existing cleaning and skin-care product can be alleviated.
Raloxifene Hydrochloride is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds. The chemical structure is: 

The chemical designation is methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[ b  ]thien-3-yl]-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, hydrochloride. Raloxifene hydrochloride (HCl) has the empirical formula C 28H 27NO 4S•HCl, which corresponds to a molecular weight of 510.04. Raloxifene Hydrochloride USP is an Almost white to pale yellow powder that freely soluble in dimethyl sulfoxide, practically insoluble in ether and in ethyl acetate. 

Raloxifene hydrochloride tablets USP, 60 mg is supplied in a tablet dosage form for oral administration. Each raloxifene hydrochloride tablets USP, 60 mg contains 60 mg of raloxifene HCl, which is the molar equivalent of 55.71 mg of free base. Inactive ingredients include citric acid monohydrate, crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, povidone and titanium dioxide.   
  
USP Dissolution Test is pending.
The invention belongs to the field of herb material processing, and more specifically relates to a preparation method of medicinal liquor prepared from walnut green seedcase, radix et caulis acanthopanacis senticosi, and sorghum spirit. The medicinal liquor is a commonly used medicinal liquor in Northeast mountains. There is a saying that walnut trees are capable of treating cancer. Walnut green seedcase is the epicarp of walnut fruits, and is also named as Qinglongyi in traditional Chinese medicine. It is found by research in recent years that walnut green seedcase is capable of killing cancer cells, can be used for treating a plurality of cancers and tumor, possesses relatively high anticancer activity on gastrointestinal tumors such as esophagus cancer, stomach cancer, and colorectal cancer, and liver cancer, and possesses excellent effect in treating gynecological cancers such as breast cancer, ovarian cancer, and cervical cancer. Regiolone is one of the main anticancer ingredient. The herb materials are cheap, anticancer effect is excellent, the medicinal liquor can be used for preventing cancer, and controlling cancer cells spreading via combination with other anticancer drugs; absorption of other Chinese and western medicines is not influenced; and the medicinal liquor also possesses certain effect on a plurality of stomach diseases, acute and chronic enteritis, and protrusion of lumbar intervertebral disc.
Dietary intervention: Participants will consume a diet that is low in saturated fat (\~5% total energy) and rich in free sugars (20% total energy).The diet will include commonly eaten food and drink such as sugar sweetened beverages, confectionery (e.g. fruit gums) and table sugar.
The proposed study will characterize the adolescent's postoperative pain and recovery experience. Using a mixed methods design, Investigators will follow a diverse cohort of up to 500 adolescents undergoing surgery at the Children's Hospital of Philadelphia (CHOP) over six months to systematically characterize their recovery trajectory. The primary objective is to characterize development of new chronic pain in the context of longitudinal pain trajectories among adolescents in the first 6 months after surgery and to quantify implications of post-surgical pain and pain treatment. The secondary objectives are to determine factors associated with prolonged opioid use after surgery compared to peers (measured in days to discontinuation) and to characterize factors associated with delayed recovery from surgery compared to peers. A baseline survey, including an anxiety and depression screen using the Patient Health Questionnaire-9 (PHQ-9) and General Anxiety Disorder-7 (GAD-7) surveys will be collected after consent and prior to surgery; subsequent post-operative surveys will be collected at one \& two weeks, one month, then monthly up to 6 months with total of 8 surveys. The PHQ-9 and GAD-7 will also be administered on month 1, month 3, and month 5. A subgroup of patients will be invited to complete a qualitative interview one month and three months after surgery (+/- 14 days). Adolescents may participate in the 3-month interview if they did not participate in the 1-month interview. The team will select adolescents who report higher pain scores compared to peers undergoing similar procedures on the Weeks 1, 2 and 3 month surveys and a sample of adolescents who are recovering as anticipated. Interviews will take place via telephone or CHOP approved videoconferencing platform with transcription and transcripts, entered in REDCap, that only contain the patient's study identification (ID) as a personal identifier. It is anticipated that some adolescents will decline participation in the one-month survey; they will not be approached to participate in the three-month survey unless they indicate willingness to receive an invitation upon submitting the Month 3 survey. It is also anticipated that individuals may decline to participate in the three-month survey and Investigators will plan to extend additional invitations to complete approximately 25 interviews at each interval.
PCT No. PCT/DK86/00007 Sec. 371 Date Nov. 5, 1986 Sec. 102(e) Date Nov. 5, 1986 PCT Filed Jan. 13, 1986 PCT Pub. No. WO86/03971 PCT Pub. Date Jul. 17, 1986.A second-step virus binding receptor is found in nature on the surface of animal and plant cells. This receptor is thought to be needed for virus penetration into target cells. The second-step receptor has been found to bind a wide variety of viruses belonging to a number of different families. The second-step receptor and natural or synthetic substances which correspond to or are analogous to the binding epitope of the second-step receptor in that they are able to bind to a site on the virus which recognizes the binding epitope of the natural second-step receptor, are therefore indicated for the diagnosis, prophylaxis or treatment of viral infections.
This group of women have tested positive for HR-HPV at annual cervical cancer screening and have been invited to participate in the study. They will be asked to use a menstrual pad we provide that collects a sample of their menstrual blood (strip). The strip will be mailed back to us for analysis (Menstrual Blood Analysis). These women will also be asked to conduct a self-swab vaginally to be sent back to us for analysis. These women will return 6-months after their positive HR-HPV for standard of care testing. All results of the standard of care tests, menstrual blood tests, and self-swab tests will be compared.
Among head and neck cancer (HNC) patients, 92% report fatigue and 73% have pain. A 10% increase in fatigue or pain is associated with a 10-25% reduction in HNC survival. During the critical transition period from the end of active treatment to 6 months post-treatment, untreated physical symptoms negatively impact functional status (ADL) and quality of life (QOL). Fatigue and musculoskeletal pain are known to improve in response to physical activity (PA). However, 51% of HNC survivors rarely engage in any type of PA because of complicated PA barriers. Our overall objective is to test an intervention to overcome these PA barriers for HNC patients during the critical transition period to self-management. PAfitME, a personalized Physical Activity intervention with fitness graded Motion Exergames, is a telehealth program built on Social Cognitive Theory and the exercise principle of adaptation. PAfitME, delivered via a tested mix of FaceTime calls and home visits, uses commercially available exergaming platforms (Wii Fit and Xbox Kinect). We propose the following specific aims: (1) When compared to an attention control group, determine the effect of PAfitME on fatigue and musculoskeletal pain at week 6, when controlling for age and sex; (2) when compared to an attention control group, determine the effect of PAfitME on functional status and QOL at week 6, when controlling for age and sex; and (3) explore if PA self-efficacy, PA enjoyment, and exergame minutes mediate the effect of PAfitME on fatigue and musculoskeletal pain. This study will evaluate 150 post-treatment (radiation, chemotherapy, or chemoradiation) HNC patients in an RCT with an attention control. For 6 weeks, the experimental (PAfitME) group will receive the PAfitME intervention, and the attention control group will receive NCI-based survivorship education and exergame equipment. For Aims 1 and 2, using an intention-to-treat framework, we will fit a series of linear mixed-effects models with each of the outcome variables. For Aim 3, we will conduct our exploratory analyses in ml_mediation (STATA 15), which will compute direct and indirect effects for multi-level data. This study aligns with the NCI Cancer Moonshot goal to minimize cancer treatment-associated side effects and the key recommendation in the National Comprehensive Cancer Network Clinical Guidelines of the need for evidence-based non- pharmacological fatigue/pain treatments (National Priority).
Poor quality of care may contribute to impaired health status and increased mortality in individuals with serious mental disorders and substance abuse problems; interventions designed to improve medical care for this population need to be developed. This study will develop a population-based medical case management model for improving the primary medical care of patients at an inner city community mental health center.

This study will last 2 years. Participants will be randomly assigned to receive medical case management or standard of care (typically drug and behavioral therapy) for 2 years. Participants in the case management group will receive help in overcoming barriers to receiving primary care. Participants will also undergo 5 interviews over the 2-year study duration, and have annual chart reviews. Results of the interviews will be used to assess quality of primary care, service use, health outcomes, psychiatric symptoms, and substance use.
One of the main reasons for hyperuricemia is high purine intake. The primary strategy for treating hyperuricemia is blocking the purine metabolism enzyme. However, by binding the purine bases directly, we suggested a unique therapeutic strategy that might interfere with purine metabolism. There have been numerous reports of extensive interactions between proteins and purine bases. Adenine, constituting numerous protein co-factors, can interact with the adenine-binding motif. Using Bayesian Inference and Markov chain Monte Carlo sampling, we created a novel adenine-binding peptide Ile-Tyr-Val-Thr based on the structure of the adenine-binding motifs. Ile-Tyr-Val-Thr generates a semi-pocket that can clip the adenine within, as demonstrated by docking. Then, using thermodynamic techniques, the interaction between Ile-Tyr-Val-Thr and adenine was confirmed. The KD value is 1.50e-5 (ΔH = -20.2 kJ/mol and ΔG = -27.6 kJ/mol), indicating the high affinity. In brief, the adenine-binding peptide Ile-Tyr-Val-Thr may help lower uric acid level by blocking the absorption of food-derived adenine.
BACKGROUND: The utilization of a different manufacturer for the prosthetic femoral head and the polyethylene insert in dual mobility (DM) for total hip arthroplasty (THA) may be necessary, especially in the revision setting. However, there is no data in the literature about this application. This study evaluated the outcomes of mixed manufacturer components, with the hypothesis that there would be no difference in measured outcomes compared to matched components.
METHODS: The DM articulations implanted during THA revision were retrospectively reviewed from 2011 to 2017. The study group was then stratified into 2 cohorts: matching components or mixed components. Of 130 hips included in the study with DM articulations with average follow-up of 7 years, 103 had mixed and 27 had matching manufacturer components. Rates of all cause reoperation and revision, intraprosthetic dislocation, dislocation, and aseptic loosening were compared using Chi-squared and Fisher's exact test; survival analysis was also performed.
RESULTS: Matched and mixed manufacturer implants had no significant difference between all cause reoperation (33 versus 25.2%), dislocation (14.8 versus 7.7%), and aseptic loosening (3.7 versus 3.9%), respectively. Higher rates of intraprosthetic dislocation (11 versus 0.97%) were observed in the matching component cohort. Survival analysis showed similar outcomes at 2, 5, and 10 years.
CONCLUSIONS: Mixed-component DM articulations show similar results compared to matching components. The off-label use of mixed manufacture DM articulation in THA is a feasible and safe option in the correct patient. Furthermore, when encountering a well-fixed femoral stem or acetabular shell, the use of a mixed component DM articulations may reduce the morbidity for the patient and prevent revision of all components.
FIELD: medicine, neurology. SUBSTANCE: invention relates to treatment of acute and chronic cerebral insufficiency and neurodegenerative diseases also. For this purpose retigabin is used that is activator of potassium channels. Invention ensures to enhance effectiveness of indicated diseases due to use of preparation eliciting expressed neuroprotective properties. EFFECT: enhanced effectiveness of treatment. 3 cl, 1 tbl
Traumatic brain injury (TBI) contributes to 50% of all trauma deaths. The mortality rate for children following severe TBI (Glasgow Coma Scale \< 9) ranges from 14-24%. There is currently no therapy to reverse the primary injury associated with TBI. Bone marrow precursor cells (BMPC) or bone marrow mononuclear cellular fractions of bone marrow contain mesenchymal stem cells (MSC) and hematopoetic stem cells (HSC). These cells are a component of bone marrow that preferentially migrate to the site of brain injury and differentiate into neurons and cell supporting elements, improving functional outcome in animals. The primary objective of this study is to determine if BMPC harvest and autologous transplantation is safe in children after TBI. The secondary objective is to determine if late functional outcome is improved with BMPC autologous transplantation compared to age and severity matched concomitant controls. Safety will be determined by monitoring cerebral and systemic hemodynamics during harvest and transplantation, neurologic events (seizure, change in GCS, stroke), local site inflammation/injury, and secondary organ injury. Late outcomes will be determined using age-corrected Glasgow Outcome Scores, and a battery of functional outcome measures. In vitro, an aliquot of cells harvested from patients will be studied for labeling with magnetodendrimers as a feasibility study, and these cells will not be reinfused into the patients. The primary endpoint is to assess the safety of autologous BMPC harvest/transplantation in the acute injury phase (hospital stay) and the secondary endpoint is to assess efficacy through 1 and 6 month post-injury follow-up. The rationale for the use of autologous BMPC transplantation is based on a large volume of in vitro and in vivo animal data (see background and significance section). The rationale for using children as the primary population is that children have a greater neurologic plasticity with a unique injury pattern when compared to adults. Children are more likely to have isolated TBI that is more diffuse and less likely to be secondary to extra-axial fluid collections. Patients aged 5-14 years old with GCS of 5-8 will be considered for enrollment into the study. Within 24-36 hours of injury, enrolled patients will undergo bone marrow harvest/BMPC separation and re-infusion. Daily monitoring of the safety outcomes measures and long term neurologic outcomes will be performed. This study should determine if bone marrow harvest, BMPC separation, and reinfusion is safe in children after severe TBI.
Use randomized controlled clinical trial design.The main content of music therapy is emotional experience , emotion regulation, emotional control and emotional expression. The experimental group received 13 group music sessions over a three-month period.
The present invention is directed toward an article of apparel configured to deliver a bioabsorbable alloy to the skin of a wearer. In an embodiment, the apparel is a textile base layer and a delivery layer oriented to contact the skin of the wearer. The delivery layer is formed from a composition including a magnesium alloy. In another embodiment, the textile is formed of strands coated with the magnesium alloy composition. In still further embodiments, the strands are formed of the alloy. The apparel may be configured to release a therapeutically effective amount to the user.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to anesthesiology, and can be used as an anaesthesia care of surgeries in degree III-IV obesity oncogynaecologic patients with no evident cardiac and pulmonary decompensation. For this purpose, a base type of blood circulation is pre-determined. The patients with hyperkinetic blood circulation require general anaesthesia by introduction of sevoflurane 1.3-1.6 MAK; 2.2-2.5 vol. % fentanyl 1.5-1.8 mcgkghour, myoplegia is performed by introduction of esmerone 0.3-0.33 mgkghour. It is combined with continuous infusion of dalargin during the whole anaesthesia in dose 45-55 mcgkghour. The patients with hypokinetic blood circulation require general anaesthesia that is combined with continuous infusion of dalargin 45-55 mcgkghour during the whole anaesthesia and infusion of magnesium sulphate 0.12-0.15 mmolekg of body weights. ^ EFFECT: method enables adequate, safe and managed anaesthesia in the case patients ensured by haemodynamic stabilisation by determined blood circulation type. ^ 2 ex
The device for light curing of dental materials for light-induced polymerization, comprises a gas tight light curing chamber (20), a first radiation source (25) for continuously radiating the light into the chamber, a second radiation source (30) for radiating visible light, which emits heat radiation into the chamber, a third radiation source (45) for generating radiation pulse, a removable swiveling storage plate (35), a drive unit (40) with a strap drive to the rotation of the plate during the light curing, and a sensor to the detection of radiation flow density of the radiation sources. The device for light curing of dental materials for light-induced polymerization, comprises a gas-tight light-curing chamber (20), a first radiation source (25) for continuously radiating the light into the chamber, a second radiation source (30) for radiating visible light, which emits heat radiation into the chamber, a third radiation source (45) for generating radiation pulse, a removable swiveling storage plate (35), a drive unit (40) with a strap drive for the rotation of the plate during the light curing, a sensor for the detection of radiation flow density of the radiation sources, and a self testing unit for comparing the recorded radiation flow density with a predetermined desired value at starting and/or with pre-determined time, and for delivering a report, if the predetermined desired value is not reached. The first radiation source shows a gas discharge lamp and/or a light diode. The second radiation source shows a halogen incandescent lamp and is arranged for warming the interior of the chamber at 150[deg]C. The third radiation source shows a xenon-flash tube and is arranged in the area of the top of the chamber. The first and the third light sources have a wavelength of 250-550 nm. The first and the second radiation sources show four radiation source units. The light-curing chamber shows a wall, a top, a bottom and a circular cross-section. The radiation units are arranged in the wall of the chamber in uniform distance. The curing chamber is separated by a divider of the radiation sources. The divider is transparent to the radiation of the radiation sources or a part of the radiation sources. Inside of the chamber is partially or completely metallized. The device shows a pump for the production of low pressure in the chamber and/or a pressure unit for the production of high pressure in the chamber. A storage area is arranged for receiving incomplete curing dental material and shows a wall that is impermeable for a curing the dental material caused by radiation. Independent claims are included for: (1) an equipment for light curing of dental material for light-induced polymerization with hand shears; and (2) system for light curing of dental material for light-induced polymerization.